查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1874402

视神经脊髓炎治疗：全球市场份额和排名、总收入和需求预测（2025-2031年）

Neuromyelitis Optica Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球视神经脊髓炎治疗药物市场规模估计为 4,980 万美元，预计到 2031 年将扩大到 6,110 万美元，2025 年至 2031 年的复合年增长率为 3.0%。

视神经脊髓炎 (NMO) 是一种罕见的中枢神经系统 (CNS) 疾病综合征，主要涉及视神经和脊髓。 NMO 患者会出现视神经炎，导致眼睛疼痛和视力丧失。横贯性脊髓炎也可能发生，导致四肢肌肉无力、麻木，有时甚至瘫痪，同时伴随感觉障碍以及膀胱和肠道功能障碍。 NMO 会导致髓鞘（一种包裹神经纤维并帮助细胞间传递神经讯号的脂肪物质）的流失。这种综合征会损伤神经纤维，并留下坏死组织区域。在 NMO 中，由于一些尚未明确的原因，免疫系统细胞和抗体会攻击并破坏视神经和脊髓中的髓鞘细胞。视神经脊髓炎药物是用于治疗该疾病的药物；在本报告中，我们重点介绍了糖皮质素（如Methylprednisolone）和免疫球蛋白（如静脉注射免疫球蛋白 (IVIG)）。

视神经脊髓炎 (NMO) 治疗市场的主要驱动力是这种罕见自体免疫疾病（也称为视神经脊髓炎频谱障碍 (NMOSD)）盛行率的上升和诊断准确性的提高。除了医疗专业人员对疾病的认识不断提高外，AQP4-IgG 抗体检测等诊断技术的进步也使得 NMO 的诊断更加早期和准确，从而增加了符合治疗条件的患者人数。此外，近期核准的标靶治疗，如Eculizumab、伊内利珠单抗和沙曲珠单抗，彻底改变了治疗格局，与传统免疫抑制剂相比，提供了更有效、特异性的治疗方法。这些突破不仅改善了患者的预后，也刺激了对 NMO 治疗研发的投资和创新。製药公司对罕见疾病的日益关注，以及孤儿药认定和快速核准等有利的监管奖励，进一步推动了市场成长。此外，医疗保健支出（尤其是在已开发地区）的成长以及患者权益倡导工作的加强，也有助于提高患者获得治疗的机会，并提高人们对这种曾经被忽视的疾病的认识。

儘管取得了令人鼓舞的进展，NMO治疗市场仍面临许多挑战，可能阻碍其长期成长。首先，新核准生物製药的高昂价格构成了一大障碍，尤其是在健保体系薄弱或缺失的中低收入国家，病患难以取得这些药物。例如，Eculizumab等药物的定价每年可达数十万美元，给医疗系统和患者都带来了沉重的负担，并可能阻碍其广泛应用。此外，NMO是一种罕见且复杂的疾病，难以招募到足够的受试者进行大规模临床试验，减缓了药物研发和创新的步伐。此疾病的表型变异性以及与多发性硬化症的症状重迭也带来了诊断挑战，可能导致误诊和不当治疗。此外，新型治疗方法的长期安全性数据仍然有限，这可能会使临床医生和监管机构在更广泛地采用这些治疗方法时感到担忧。最后，该市场仍然高度专业化，製药公司数量有限，限制了竞争，并造成了供应链的脆弱性。如果 NMO 治疗领域的最新进展要转化为各种医疗保健环境中患者疗效的改善，那么应对这些挑战至关重要。

本报告旨在按地区/国家、类型和应用对全球视神经脊髓炎治疗市场进行全面分析，重点关注总销售额、市场份额和主要企业的排名。

本报告中关于脊髓炎治疗药物市场规模、估算和预测的数据均以收益为准，以2024年为基准年，并涵盖2020年至2031年的历史数据和预测数据。报告的定量和定性分析将帮助读者制定脊髓炎治疗药物的业务和成长策略，评估市场竞争，分析公司在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Pfizer
  • Fresenius
  • Teva
  • Sandoz
  • Intas
  • Gyjtrs
  • NANG KUANG
  • Tianjin Kingyork
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • CBOP

按类型分類的细分市场

  • 糖皮质素
  • 免疫疗法
  • 其他的

应用领域

  • 急性发作
  • 缓解期预防性治疗

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Neuromyelitis Optica Drug was estimated to be worth US$ 49.8 million in 2024 and is forecast to a readjusted size of US$ 61.1 million by 2031 with a CAGR of 3.0% during the forecast period 2025-2031.

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord. Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

The Neuromyelitis Optica (NMO) drug market is being significantly driven by the rising prevalence and improved diagnosis of this rare autoimmune disorder, also known as Neuromyelitis Optica Spectrum Disorder (NMOSD). Increased awareness among healthcare professionals, coupled with advancements in diagnostic technologies such as AQP4-IgG antibody testing, has led to earlier and more accurate diagnosis of NMO, thereby increasing the number of patients eligible for treatment. Furthermore, the approval of targeted therapies like eculizumab, inebilizumab, and satralizumab in recent years has transformed the treatment landscape, offering more effective and specific interventions compared to traditional immunosuppressants. These breakthroughs have not only improved patient outcomes but have also stimulated investment and innovation in NMO drug development. The growing focus on orphan diseases by pharmaceutical companies, supported by favorable regulatory incentives such as orphan drug designations and fast-track approvals, is further fueling market growth. In addition, increasing healthcare expenditure, especially in developed regions, and a stronger patient advocacy movement are contributing to greater access to treatment and awareness about this once-overlooked condition.

Despite promising developments, the NMO drug market faces several challenges that may hinder its long-term growth. First, the high cost of newly approved biologic therapies poses a significant barrier to access, particularly in low- and middle-income countries where reimbursement systems are weak or nonexistent. The pricing of drugs like eculizumab, which can cost hundreds of thousands of dollars per year, places a heavy burden on both healthcare systems and patients, potentially limiting widespread adoption. Additionally, NMO is a rare and complex disease, which makes it difficult to recruit sufficient participants for large-scale clinical trials, slowing the pace of drug development and innovation. The heterogeneity of disease presentation and overlapping symptoms with multiple sclerosis also pose diagnostic challenges, which can lead to misdiagnosis and inappropriate treatment. Moreover, long-term safety data for newer therapies are still limited, which may create hesitation among clinicians and regulatory bodies when adopting these treatments on a broader scale. Lastly, the market remains highly specialized, with few pharmaceutical players involved, leading to limited competition and potential supply chain vulnerabilities. Addressing these issues will be essential to ensuring that recent advancements in NMO treatment translate into improved outcomes for patients across different healthcare environments.

This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Neuromyelitis Optica Drug by region & country, by Type, and by Application.

The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.

Market Segmentation

By Company

  • Pfizer
  • Fresenius
  • Teva
  • Sandoz
  • Intas
  • Gyjtrs
  • NANG KUANG
  • Tianjin Kingyork
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • CBOP

Segment by Type

  • Glucocorticoids
  • Immunotherapies
  • Others

Segment by Application

  • Acute Attack
  • Remission Prophylactic Treatment

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Neuromyelitis Optica Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Neuromyelitis Optica Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Neuromyelitis Optica Drug in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Neuromyelitis Optica Drug Product Introduction
  • 1.2 Global Neuromyelitis Optica Drug Market Size Forecast (2020-2031)
  • 1.3 Neuromyelitis Optica Drug Market Trends & Drivers
    • 1.3.1 Neuromyelitis Optica Drug Industry Trends
    • 1.3.2 Neuromyelitis Optica Drug Market Drivers & Opportunity
    • 1.3.3 Neuromyelitis Optica Drug Market Challenges
    • 1.3.4 Neuromyelitis Optica Drug Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Neuromyelitis Optica Drug Players Revenue Ranking (2024)
  • 2.2 Global Neuromyelitis Optica Drug Revenue by Company (2020-2025)
  • 2.3 Key Companies Neuromyelitis Optica Drug Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Neuromyelitis Optica Drug Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Neuromyelitis Optica Drug
  • 2.6 Neuromyelitis Optica Drug Market Competitive Analysis
    • 2.6.1 Neuromyelitis Optica Drug Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Neuromyelitis Optica Drug Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Glucocorticoids
    • 3.1.2 Immunotherapies
    • 3.1.3 Others
  • 3.2 Global Neuromyelitis Optica Drug Sales Value by Type
    • 3.2.1 Global Neuromyelitis Optica Drug Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Neuromyelitis Optica Drug Sales Value, by Type (2020-2031)
    • 3.2.3 Global Neuromyelitis Optica Drug Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Acute Attack
    • 4.1.2 Remission Prophylactic Treatment
  • 4.2 Global Neuromyelitis Optica Drug Sales Value by Application
    • 4.2.1 Global Neuromyelitis Optica Drug Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Neuromyelitis Optica Drug Sales Value, by Application (2020-2031)
    • 4.2.3 Global Neuromyelitis Optica Drug Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Neuromyelitis Optica Drug Sales Value by Region
    • 5.1.1 Global Neuromyelitis Optica Drug Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Neuromyelitis Optica Drug Sales Value by Region (2020-2025)
    • 5.1.3 Global Neuromyelitis Optica Drug Sales Value by Region (2026-2031)
    • 5.1.4 Global Neuromyelitis Optica Drug Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.2.2 North America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.3.2 Europe Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Neuromyelitis Optica Drug Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.5.2 South America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Neuromyelitis Optica Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Neuromyelitis Optica Drug Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.3.2 United States Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.4.2 Europe Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.5.2 China Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.6.2 Japan Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.7.2 South Korea Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Neuromyelitis Optica Drug Sales Value, 2020-2031
    • 6.9.2 India Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Neuromyelitis Optica Drug Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Pfizer
    • 7.1.1 Pfizer Profile
    • 7.1.2 Pfizer Main Business
    • 7.1.3 Pfizer Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.1.4 Pfizer Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Pfizer Recent Developments
  • 7.2 Fresenius
    • 7.2.1 Fresenius Profile
    • 7.2.2 Fresenius Main Business
    • 7.2.3 Fresenius Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.2.4 Fresenius Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Fresenius Recent Developments
  • 7.3 Teva
    • 7.3.1 Teva Profile
    • 7.3.2 Teva Main Business
    • 7.3.3 Teva Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.3.4 Teva Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Teva Recent Developments
  • 7.4 Sandoz
    • 7.4.1 Sandoz Profile
    • 7.4.2 Sandoz Main Business
    • 7.4.3 Sandoz Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.4.4 Sandoz Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Sandoz Recent Developments
  • 7.5 Intas
    • 7.5.1 Intas Profile
    • 7.5.2 Intas Main Business
    • 7.5.3 Intas Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.5.4 Intas Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Intas Recent Developments
  • 7.6 Gyjtrs
    • 7.6.1 Gyjtrs Profile
    • 7.6.2 Gyjtrs Main Business
    • 7.6.3 Gyjtrs Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Gyjtrs Recent Developments
  • 7.7 NANG KUANG
    • 7.7.1 NANG KUANG Profile
    • 7.7.2 NANG KUANG Main Business
    • 7.7.3 NANG KUANG Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.7.5 NANG KUANG Recent Developments
  • 7.8 Tianjin Kingyork
    • 7.8.1 Tianjin Kingyork Profile
    • 7.8.2 Tianjin Kingyork Main Business
    • 7.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Tianjin Kingyork Recent Developments
  • 7.9 Baxter
    • 7.9.1 Baxter Profile
    • 7.9.2 Baxter Main Business
    • 7.9.3 Baxter Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.9.4 Baxter Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Baxter Recent Developments
  • 7.10 CSL
    • 7.10.1 CSL Profile
    • 7.10.2 CSL Main Business
    • 7.10.3 CSL Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.10.4 CSL Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.10.5 CSL Recent Developments
  • 7.11 Grifols
    • 7.11.1 Grifols Profile
    • 7.11.2 Grifols Main Business
    • 7.11.3 Grifols Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.11.4 Grifols Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Grifols Recent Developments
  • 7.12 Octapharma
    • 7.12.1 Octapharma Profile
    • 7.12.2 Octapharma Main Business
    • 7.12.3 Octapharma Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.12.4 Octapharma Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Octapharma Recent Developments
  • 7.13 CBOP
    • 7.13.1 CBOP Profile
    • 7.13.2 CBOP Main Business
    • 7.13.3 CBOP Neuromyelitis Optica Drug Products, Services and Solutions
    • 7.13.4 CBOP Neuromyelitis Optica Drug Revenue (US$ Million) & (2020-2025)
    • 7.13.5 CBOP Recent Developments

8 Industry Chain Analysis

  • 8.1 Neuromyelitis Optica Drug Industrial Chain
  • 8.2 Neuromyelitis Optica Drug Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Neuromyelitis Optica Drug Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Neuromyelitis Optica Drug Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Neuromyelitis Optica Drug Market Trends
  • Table 2. Neuromyelitis Optica Drug Market Drivers & Opportunity
  • Table 3. Neuromyelitis Optica Drug Market Challenges
  • Table 4. Neuromyelitis Optica Drug Market Restraints
  • Table 5. Global Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Neuromyelitis Optica Drug Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Neuromyelitis Optica Drug Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Neuromyelitis Optica Drug Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Neuromyelitis Optica Drug
  • Table 10. Global Neuromyelitis Optica Drug Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Neuromyelitis Optica Drug Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Neuromyelitis Optica Drug Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Neuromyelitis Optica Drug Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Neuromyelitis Optica Drug Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Neuromyelitis Optica Drug Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Neuromyelitis Optica Drug Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Neuromyelitis Optica Drug Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Neuromyelitis Optica Drug Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Neuromyelitis Optica Drug Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Neuromyelitis Optica Drug Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Neuromyelitis Optica Drug Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Neuromyelitis Optica Drug Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Neuromyelitis Optica Drug Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Neuromyelitis Optica Drug Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Neuromyelitis Optica Drug Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Neuromyelitis Optica Drug Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Neuromyelitis Optica Drug Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Neuromyelitis Optica Drug Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Pfizer Basic Information List
  • Table 32. Pfizer Description and Business Overview
  • Table 33. Pfizer Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Pfizer (2020-2025)
  • Table 35. Pfizer Recent Developments
  • Table 36. Fresenius Basic Information List
  • Table 37. Fresenius Description and Business Overview
  • Table 38. Fresenius Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Fresenius (2020-2025)
  • Table 40. Fresenius Recent Developments
  • Table 41. Teva Basic Information List
  • Table 42. Teva Description and Business Overview
  • Table 43. Teva Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Teva (2020-2025)
  • Table 45. Teva Recent Developments
  • Table 46. Sandoz Basic Information List
  • Table 47. Sandoz Description and Business Overview
  • Table 48. Sandoz Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Sandoz (2020-2025)
  • Table 50. Sandoz Recent Developments
  • Table 51. Intas Basic Information List
  • Table 52. Intas Description and Business Overview
  • Table 53. Intas Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Intas (2020-2025)
  • Table 55. Intas Recent Developments
  • Table 56. Gyjtrs Basic Information List
  • Table 57. Gyjtrs Description and Business Overview
  • Table 58. Gyjtrs Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Gyjtrs (2020-2025)
  • Table 60. Gyjtrs Recent Developments
  • Table 61. NANG KUANG Basic Information List
  • Table 62. NANG KUANG Description and Business Overview
  • Table 63. NANG KUANG Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of NANG KUANG (2020-2025)
  • Table 65. NANG KUANG Recent Developments
  • Table 66. Tianjin Kingyork Basic Information List
  • Table 67. Tianjin Kingyork Description and Business Overview
  • Table 68. Tianjin Kingyork Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Tianjin Kingyork (2020-2025)
  • Table 70. Tianjin Kingyork Recent Developments
  • Table 71. Baxter Basic Information List
  • Table 72. Baxter Description and Business Overview
  • Table 73. Baxter Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Baxter (2020-2025)
  • Table 75. Baxter Recent Developments
  • Table 76. CSL Basic Information List
  • Table 77. CSL Description and Business Overview
  • Table 78. CSL Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of CSL (2020-2025)
  • Table 80. CSL Recent Developments
  • Table 81. Grifols Basic Information List
  • Table 82. Grifols Description and Business Overview
  • Table 83. Grifols Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Grifols (2020-2025)
  • Table 85. Grifols Recent Developments
  • Table 86. Octapharma Basic Information List
  • Table 87. Octapharma Description and Business Overview
  • Table 88. Octapharma Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of Octapharma (2020-2025)
  • Table 90. Octapharma Recent Developments
  • Table 91. CBOP Basic Information List
  • Table 92. CBOP Description and Business Overview
  • Table 93. CBOP Neuromyelitis Optica Drug Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Neuromyelitis Optica Drug Business of CBOP (2020-2025)
  • Table 95. CBOP Recent Developments
  • Table 96. Key Raw Materials Lists
  • Table 97. Raw Materials Key Suppliers Lists
  • Table 98. Neuromyelitis Optica Drug Downstream Customers
  • Table 99. Neuromyelitis Optica Drug Distributors List
  • Table 100. Research Programs/Design for This Report
  • Table 101. Key Data Information from Secondary Sources
  • Table 102. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Neuromyelitis Optica Drug Product Picture
  • Figure 2. Global Neuromyelitis Optica Drug Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Neuromyelitis Optica Drug Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Neuromyelitis Optica Drug Report Years Considered
  • Figure 5. Global Neuromyelitis Optica Drug Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Neuromyelitis Optica Drug Revenue in 2024
  • Figure 7. Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Glucocorticoids Picture
  • Figure 9. Immunotherapies Picture
  • Figure 10. Others Picture
  • Figure 11. Global Neuromyelitis Optica Drug Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Neuromyelitis Optica Drug Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Acute Attack
  • Figure 14. Product Picture of Remission Prophylactic Treatment
  • Figure 15. Global Neuromyelitis Optica Drug Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global Neuromyelitis Optica Drug Sales Value Market Share by Application, 2024 & 2031
  • Figure 17. North America Neuromyelitis Optica Drug Sales Value (2020-2031) & (US$ Million)
  • Figure 18. North America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 19. Europe Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 20. Europe Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Asia Pacific Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Asia Pacific Neuromyelitis Optica Drug Sales Value by Region (%), 2024 VS 2031
  • Figure 23. South America Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. South America Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 25. Middle East & Africa Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. Middle East & Africa Neuromyelitis Optica Drug Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Key Countries/Regions Neuromyelitis Optica Drug Sales Value (%), (2020-2031)
  • Figure 28. United States Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. United States Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 30. United States Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 31. Europe Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Europe Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 33. Europe Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 34. China Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. China Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 36. China Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 37. Japan Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. Japan Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 39. Japan Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 40. South Korea Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. South Korea Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 42. South Korea Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 43. Southeast Asia Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. Southeast Asia Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 45. Southeast Asia Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 46. India Neuromyelitis Optica Drug Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. India Neuromyelitis Optica Drug Sales Value by Type (%), 2024 VS 2031
  • Figure 48. India Neuromyelitis Optica Drug Sales Value by Application (%), 2024 VS 2031
  • Figure 49. Neuromyelitis Optica Drug Industrial Chain
  • Figure 50. Neuromyelitis Optica Drug Manufacturing Cost Structure
  • Figure 51. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 52. Bottom-up and Top-down Approaches for This Report
  • Figure 53. Data Triangulation
  • Figure 54. Key Executives Interviewed